Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications
about
Antimitotic drugs in the treatment of cancerAnalysis of different HER-2 mutations in breast cancer progression and drug resistanceCurrent treatment of early breast cancer: adjuvant and neoadjuvant therapyOverview of the CLEOPATRA Trial: Implications for Advanced PractitionersMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesErbB polymorphisms: insights and implications for response to targeted cancer therapeuticsExamining the pathogenesis of breast cancer using a novel agent-based model of mammary ductal epithelium dynamicsInduction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancert-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer CellsClonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- VinorelbineEpidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases.Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast CancerZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.Targeting the disordered C terminus of PTP1B with an allosteric inhibitorCurrent Approaches and Emerging Directions in HER2-resistant Breast Cancer.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells.An Introspective Update on the Influence of miRNAs in Breast Carcinoma and Neuroblastoma ChemoresistanceResistance to HER2-targeted therapies: a potential role for FOXM1.Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors.Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2Oncogenic HER2 fusions in gastric cancer.Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growthMolecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.Essential medicines for breast cancer in low and middle income countries.Molecular targeted α-particle therapy for oncologic applications.Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy.Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy.The Major Prognostic Features of Nuclear Receptor NR5A2 in Infiltrating Ductal Breast Carcinomas.In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.An anti-ErbB2 fully human antibody circumvents trastuzumab resistance.Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyBayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancerMicroenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
P2860
Q26777317-F422C82C-7FB2-4518-94C2-661B95BBFA00Q26797471-4167785F-EC0A-4742-BE34-3A0186330F4FQ27011658-C9A7E370-8138-401E-83E7-5DA2843BE5FBQ28066819-9F808F5E-FA6D-4A78-8A54-741373E28893Q28072513-74B7443A-A521-4DC5-84D5-60BB5BC21688Q28072897-37676319-76FD-4769-AC27-D44C9A47385DQ28084565-AF3EF243-0ECC-49EB-BC28-4C5CF6BA8D95Q28383242-018D8308-CC22-436C-98C9-6A37F5EF41E4Q28534358-C5EBD00C-1414-4BF1-B2D2-8D220B401D98Q28545954-8AEC3560-B6EA-47C6-935D-728B1B29BDB8Q28554790-0C38164F-74A9-46B4-A5FB-2921D4882954Q30412086-41090978-7F66-42B0-BB79-CE49D60AA10DQ30713425-1354F791-81C7-45BA-82E2-9939CCD2F502Q30857631-9A514C07-F93A-49B6-89C6-A5FAD0C04F82Q33576608-8C70689E-95F5-4DAC-8D9D-8B5F8B14749CQ33685931-0AD6A810-8108-45D1-A05B-4B1FCCCDF08EQ33774262-B2D3405E-A27F-4DDC-BC19-701FC6949533Q34016480-FC419F51-8DF0-4712-AC29-970465F94374Q34147910-FE768A26-D7F8-4B3D-AA5A-5BD6E513C511Q34713726-9AF1AE77-FD82-46B5-89D0-E2EFDC5C5EB7Q34753903-8492A11E-1FB5-4D1B-AB62-B41C79248291Q34955355-E3D13E71-049D-4628-82FE-2A1D94D61389Q35127865-9544B5D3-3652-4BD0-A642-2F45CFB6C93FQ35273305-6C5BCA62-4DF2-4A6B-A16D-7700C6C021B3Q35414389-76A2AE6D-B068-48A1-AB5D-62E20B8E941DQ35533503-98C38D0E-21A8-4D52-A5F1-7FB42984CAC7Q35626610-51A6A680-AEBF-49EF-922A-9552CB11D311Q35663802-FF0BA0C7-D2EE-47F4-8FAC-2B541F942D9DQ35748465-A34FE04E-E6DD-4C4F-BDC7-6CDADB418336Q35814989-86480BBA-EB64-4CC8-9171-CAC77C6E98BDQ35836089-94C12494-F734-4081-A3FF-A07847B980D9Q35849919-4B1F744A-7DE9-4293-BDC8-E0AE2609954FQ36021424-068D5009-58CF-4466-855C-8F894559FC01Q36031258-6B844154-12E9-4BE4-9133-3817BEDE92DAQ36109108-51C8F16C-753C-42FA-A834-A9E652A4860EQ36114109-E2DA9554-1693-4234-9E1D-11AF65F04B52Q36288976-76B6A3A7-5188-4773-A7E1-067FCEAF07B9Q36306149-029ACB20-D21D-47B0-ACB3-A25D01D4469CQ36455404-5F552D2A-C1FE-4CF5-9F62-3F0248E0444AQ36545717-FF9F98D2-EA6B-4F6C-B18E-B0C2BC0E7FD3
P2860
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Intrinsic and acquired resista ...... isms and clinical implications
@ast
Intrinsic and acquired resista ...... isms and clinical implications
@en
type
label
Intrinsic and acquired resista ...... isms and clinical implications
@ast
Intrinsic and acquired resista ...... isms and clinical implications
@en
prefLabel
Intrinsic and acquired resista ...... isms and clinical implications
@ast
Intrinsic and acquired resista ...... isms and clinical implications
@en
P2860
P1476
Intrinsic and acquired resista ...... isms and clinical implications
@en
P2093
Brent N Rexer
Carlos L Arteaga
P2860
P356
10.1615/CRITREVONCOG.V17.I1.20
P407
P577
2012-01-01T00:00:00Z